Nuwellis announces findings from ULTRA-Peds registry on Aquadex System use

Nuwellis, Inc. (NASDAQ:NUWE) announced findings Monday from the ULTRA-Peds registry, a multi-center observational study evaluating the real-world use of the Aquadex System in pediatric patients. The study focused on children diagnosed with acute kidney injury, fluid overload, or congenital kidney failure. The company, which maintains a healthy balance sheet with more cash than debt and a current ratio of 2.16, continues to invest in clinical research despite challenging market conditions.

According to the company’s statement, the ULTRA-Peds registry compiled data from multiple centers to assess the application of the Aquadex System in these patient populations. The company did not disclose specific results or outcomes from the study in the filing.

Nuwellis, headquartered in Eden Prairie, Minnesota, develops medical devices for fluid management. The Aquadex System is designed to help manage fluid overload, a condition that can occur in patients with kidney-related illnesses.

The announcement was made as part of a filing with the U.S. Securities and Exchange Commission. No additional financial information or guidance was provided in the statement.

This article is based on a press release statement included in a recent SEC filing.

In other recent news, Nuwellis, Inc. reported a 92% survival rate in a study involving pediatric patients treated with its Aquadex ultrafiltration system. The study included 91 children across eight U.S. centers, focusing on those with acute kidney injury, fluid overload, or congenital kidney failure. Additionally, Nuwellis was granted a U.S. patent for its hemolysis sensor technology, which is used in extracorporeal blood filtration systems to detect red blood cell destruction. This patent is expected to support the development of Nuwellis’s pediatric device, Vivian, and future innovations. Furthermore, the National Institutes of Health awarded approximately $3 million to Koronis Biomedical Technologies Corporation, Nuwellis’s development partner, to advance the Vivian device for pediatric continuous renal replacement therapy. Meanwhile, New Era Energy & Digital, Inc. announced a major fiber network development deal through its joint venture with Texas Critical Data Centers LLC. The agreement involves developing a 1,600-mile fiber optic network across Texas, aimed at supporting artificial intelligence, hyperscale, and cloud workloads.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.